We therefore suggested that the effects of renin and its inhibitor aliskiren would be most pronounced in the kidney, especially in complement-mediated diseases, such as C3 glomerulopathy, and that systemic levels of C3 could still be low due to the presence of nephritic factors or complement gene variants (4). This evidence concerns the gene C3 and complement 3 glomerulopathy.